These results demonstrate that inhibiting ferroptosis, rather than activating the AMPK pathway, is the primary mechanism of action of metformin against IIRI
However, the pivotal 36-week Phase 2 trial showed a larger range of mean loss, from 9.4% to 14.7%, across doses, confirming robust dose-dependent effects
Other predisposing factors include obesity, immunosuppression, antibiotic use, pregnancy, tight-fitting synthetic clothing, and poor personal hygiene practices
Bee pollen and bee bread as a source of Bacteria producing antimicrobials
Yeast infections are not associated with GLP-1 agonists like Ozempic